Mannkind, Game-Chancer in Sachen Diabetik? (Seite 197)

[Aurum2010]

Antwort auf Beitrag Nr.: 58.625.889 von Aurum2010 am 05.09.18 21:22:11

Zitat von Aurum2010:

Zitat von questionmark: Jetzt wird wieder geschüttelt, so ein Mist

War zu erwarten:
http://investors.mannkindcorp.com/node/15831/html

Lest mal diese gestrige MNKD Meldung, seitdem geht der Kurs wieder gegen Süden.

[peppino23]

Jetzt wird schon massiv dagegen gehalten!
Wenn das mal nicht in die Hose geht
Mitleid können sich die Shorts von uns nicht erwarten, oder?
Mannkind wird raufgehen und zwar ordentlich.
Total unterbewertet, derzeit.... $ 4 müssen auf alle Fälle drinnen sein, bei den Zukunftsaussichten und die Börse handelt normal die Zukunft. Verkauft, verkauft, verkauft und irgendwann müsst ihr wieder ZUKAUFEN!!! Ein Moment der Freude.

[pulloverschaf]

Antwort auf Beitrag Nr.: 58.635.348 von questionmark am 06.09.18 19:39:41

Ich verstehe es nicht bei so einer news das es so wieder down geht der Kurs hat immer recht unter 2 bin ich raus dann gehts auch wieder Richtung 1,20 so hab ich immernoch genug Gewinne

[questionmark]

Na hoffentlich hält die 2, hätte ich mal verkauft neulich...

[1Fuchs]

Antwort auf Beitrag Nr.: 58.632.867 von Magnetfeldfredy am 06.09.18 16:14:19

Hier wurden heute bereits wieder 8 Mio Aktien in nicht einmal einer Stunde gehandelt. Die letzten beiden Tage über 140 Mio Aktien. Schon verrückt.

[Magnetfeldfredy]

Gute Zusammenfassung:

New Development Partnership Could Pay Off Big for MannKind Stock
[InvestorPlace]
Chris Lau
,InvestorPlace•September 5, 2018

After spending much of 2017 in a downtrend, MannKind (NASDAQ:MNKD) lit up on the stock market and closed above $2.00 a share on Sept. 4 for the first time since June.

The company announced that it would collaborate with United Therapeutics (NASDAQ:UTHR) on treprostinil, an investigational drug for the treatment of pulmonary arterial hypertension. The cash infusion from the deal is just what MannKind needed.

United Therapeutics will pay MannKind $45 million upfront and reward the company an additional $50 million in potential milestone payments for developing and commercializing a dry-powder formulation of treprostnil.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

The product is currently under evaluation through clinical trials. If the product reaches the market, MannKind will get low double-digit percentage royalties on net sales of the product. The company also gets up to $40 million for every additional option exercise, and development milestone payments.

7 Blue-Chip Stocks to Sell Now

The partnership does not end there. United will pay $10 million immediately for product development outside the scope of the agreement. The deal is a big win for MannKind, which previously had limited potential without a partner as big as United Therapeutics.

The $95-million upfront payment for treprostnil development may also lead to another development opportunity for the micro-cap biotech firm. MannKind also developed Afrezza, but it could never make it commercially. Now, with support from United, the upfront funds invested is a vote of confidence for the firm.
More Upside for MannKind Stock

MannKind stock’s 89% pop on Sep. 4 could be just the start of a longer-term uptrend. The company reported quarterly sales of $3.8 million for Afrezza, up 153.3% from last year.

The commercialization of treprostnil will more than accelerate the company’s much-needed revenue growth in the quarters ahead. This is troubling for short sellers (22.63% of the float is short), and they will face further losses if MannKind stock continues to move higher.

Before its deal with United, MannKind reported an unsustainable negative free cash flow. Cash, cash equivalents and restricted cash at Jun. 30, 2018, fell to $26.7 million. On Dec. 31, 2017, cash was $48.4 million.

Now, the partnership negates the cash flow concern and undermines the bearish bet against the company. The short squeeze over the course of the next few days could help MNKD stock in a positive way.
Fair Value on MNKD Stock

Only one analyst offered a price target on MannKind stock, setting a $4 price target, or over 90% upside. Though it is too early to predict, the company has a better chance of moving higher not just on the commercialization of treprostnil, but also because it could develop new products with the additional $10 million it has available for spending on research and development.

Why MannKind Stock Is Skyrocketing Today

Using a 10-year DCF Revenue Exit model, at a discount rate of between 12-14%, MNKD shares are worth between $2.05 to $2.73 with an average fair value of around $2.40. This assumes MannKind’s revenue will grow in the range of 20-25% starting in FY 2019. Readers may enter their own assumptions on finbox.io with this link.

[price-of-success]

Männer:
folgende neue Milestones notwendig:

morgen über 600 TRX

Brasilien Zulassung

und abbau der short Position

IMO

Gruß

PS: was sagt die Kollegin im Zimmer nebenan? gerne antwort per whatts app oder BM

[Magnetfeldfredy]

Die Zweifler wurden eines Besseren belehrt, Mannkind ist kein one trick pony mehr, 95 Millionen upfront sind garantiert, zweistellige Prozente der sales gesichert und das kann auf viele andere Indikationen ausgeweitet werden, ja wir leben und werden es noch Allen zeigen, vor dem Deal war es Spitz auf Kopf, jetzt bin ich relaxt was die Zukunft angeht!

[pulloverschaf]

Antwort auf Beitrag Nr.: 58.632.576 von Magnetfeldfredy am 06.09.18 15:50:52

Das kann doch nur up gehen wenn die Shorts fertig sind

[Magnetfeldfredy]

Jetzt amtlich:


tem 1.01 Entry into a Material Definitive Agreement.
On September 3, 2018, MannKind Corporation (“MannKind”) and United Therapeutics Corporation (“United Therapeutics”) entered into an exclusive
global license and collaboration agreement (the “License Agreement”) for the rights to MannKind’s dry powder formulation of treprostinil (the “API”)
and inhalation delivery devices associated with the API (the “Devices”), both in combination with one another and separately (the API and the
Devices, together and separately, the “Product”). Under the License Agreement, United Therapeutics will be responsible for global development,
regulatory and commercial activities with respect to the Product. MannKind will manufacture clinical supplies and initial commercial supplies of the
Product, and long-term commercial supplies will be manufactured by United Therapeutics.
Under the terms of the License Agreement, MannKind will receive an upfront payment of $45 million within 10 business days following the
effectiveness of the License Agreement and potential milestone payments of up to $50 million upon the achievement of specified development targets.
MannKind will also be entitled to receive low double-digit royalties on net sales of the Product. At United Therapeutics’ option, United Therapeutics
may expand the scope of the Products covered by the License Agreement to include products with certain other active ingredients for the treatment of
pulmonary hypertension. Each such optioned product would be subject to United Therapeutics’ payment to MannKind of up to $40 million in
additional option exercise and development milestone payments, as well as a low double-digit royalty on net sales of any such product.
United Therapeutics and MannKind may each terminate the License Agreement for material breach by the other party that is not cured within a specific
time frame or in the event of liquidation, bankruptcy or insolvency of the other party. In addition, United Therapeutics may terminate the License
Agreement, in its entirety or with respect to a particular Product, upon 90 days’ prior written notice to MannKind. MannKind may terminate the
License Agreement upon a change of control of United Therapeutics if such change of control is reasonably anticipated to result in a material reduction
in net sales of Products or access to manufacturing information by a party with very competitive products or pipelines to MannKind’s products.
The effectiveness of the License Agreement is conditioned upon expiration or termination of the required waiting period under the Hart-Scott-Rodino
Antitrust Improvements Act.
On September 3, 2018, MannKind and United Therapeutics also entered into a research agreement (the “Research Agreement”) for the conduct of
research by MannKind in connection with multiple potential products, including evaluating the feasibility of preparing a dry powder formulation of a
compound within additional classes of active ingredients (outside the scope of the License Agreement) for the treatment of pulmonary hypertension.
MannKind received an upfront payment of $10 million in consideration for its performance under the Research Agreement. In addition, United
Therapeutics, at its option, may obtain a license to develop, manufacture and commercialize products based on specified compounds within the drug
classes covered by the Research Agreement (the “Option”). Each specified compound advanced into development and commercialization under such a
license would be subject to the payment to MannKind of additional milestone payments of up to $30 million and a low double-digit royalty on net
sales of such products. The Research Agreement will terminate in the event that United Therapeutics does not exercise the Option within five years
following the date of the Research Agreement, or in the event United Therapeutics exercises the Option and the parties enter into a separate license
agreement as contemplated by the Option. United Therapeutics may terminate the Research Agreement without cause upon 30 days’ prior written
notice to MannKind, and either party may terminate the Research Agreement in the event of liquidation, bankruptcy or insolvency of the other party.
The foregoing description of the License Agreement and Research Agreement is only a summary and is qualified in its entirety by reference to the
License Agreement and the Research Agreement, copies of which will be filed as exhibits to MannKind’s quarterly report on
Form 10-Q
for the quarter
ended September 30, 2018